Krilogy Financial LLC Buys Shares of 10,500 IQVIA Holdings Inc. (NYSE:IQV)

Krilogy Financial LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,500 shares of the medical research company's stock, valued at approximately $1,851,000.

A number of other hedge funds also recently bought and sold shares of the stock. American National Bank & Trust acquired a new position in IQVIA during the 1st quarter worth approximately $26,000. ST Germain D J Co. Inc. increased its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in IQVIA in the fourth quarter valued at $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth about $44,000. Finally, Zions Bancorporation N.A. increased its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on IQV shares. Robert W. Baird cut their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price target for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Finally, Mizuho decreased their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Trading Down 1.6%

IQV stock traded down $2.48 during trading on Friday, reaching $156.65. 1,473,864 shares of the stock traded hands, compared to its average volume of 1,616,081. The firm has a market capitalization of $27.10 billion, a PE ratio of 20.89, a P/E/G ratio of 1.99 and a beta of 1.28. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business's 50 day moving average price is $147.59 and its 200-day moving average price is $177.68. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. IQVIA's revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.54 earnings per share. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.